Last €35.96 EUR
Change Today +0.008 / 0.02%
Volume 4.3K
NOVA On Other Exchanges
Symbol
Exchange
Copenhagen
New York
Frankfurt
Frankfurt
As of 11:42 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€35.60
Previous Close
€35.95
Day High
€36.41
Day Low
€35.60
52 Week High
10/1/14 - €38.67
52 Week Low
12/17/13 - €24.95
Market Cap
95.3B
Average Volume 10 Days
1.8K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/21/14
P/E TM
--
Dividend
€0.75
Dividend Yield
1.67%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

37,978 Employees
Last Reported Date: 02/5/14
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr7.0M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk A/S Presents at HSBC Healthcare Day 2014, Nov-12-2014

Novo Nordisk A/S Presents at HSBC Healthcare Day 2014, Nov-12-2014 . Venue: Hilton, Frankfurt, Germany.

Novo Nordisk A/S Presents at BIO-Europe 2014, Nov-03-2014 through Nov-05-2014

Novo Nordisk A/S Presents at BIO-Europe 2014, Nov-03-2014 through Nov-05-2014. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Presentation Date & Speakers: Nov-03-2014, Tomas Landh, Director, Strategy and Innovation Sourcing, Diabetes Research Unit.

Novo Nordisk Invests DKK 750 Million in New Laboratories for Diabetes Research in Denmark

Novo Nordisk announced an investment of approximately DKK 750 million in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready for occupation in early 2016. The new facility - Diabetes Research House will accommodate approximately 350 employees. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk. The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people. The facility will have a floorage of 16,500 square metres distributed on three storeys.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €35.96 EUR +0.008

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.64 USD +0.28
Biogen Idec Inc $305.98 USD +2.43
Bristol-Myers Squibb Co $58.78 USD -0.02
Eli Lilly & Co $66.90 USD -0.46
Reckitt Benckiser Group PLC 5,180 GBp +20.00
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 26.5x
Price/Sales 7.9x
Price/Book 17.9x
Price/Cash Flow 21.2x
TEV/Sales 6.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.